Intellia Therapeutics, Inc.

Intellia Therapeutics is a clinical-stage biopharmaceutical company built around CRISPR-based gene editing and related delivery technologies. It is developing potentially curative therapies for severe genetic diseases, with its lead programs lonvoguran ziclumeran (NTLA-2002) for hereditary angioedema and nexiguran ziclumeran (NTLA-2001) for ATTR amyloidosis in Phase 3 development.

−637,2 %

−609,9 %

+16,9 %

5.08

5.08

— Intellia Therapeutics, Inc.
%
In vivo gene editing therapeutics0% Systemically administered CRISPR-based drug candidates designed to durably edit disease-causing genes in the body.
Lead clinical programs0% NTLA-2002 and NTLA-2001, the company's most advanced programs targeting HAE and ATTR amyloidosis.
Delivery platform technologies0% Oligonucleotide and lipid nanoparticle tools used to enable targeted in vivo gene editing.
Collaboration revenue100% Upfront fees, research funding, cost reimbursements, and milestones from strategic partners.

Intellia does not yet sell approved medicines directly to patients; its current customers are collaboration partners...

  • Strategic collaboration partnersprimary

    Regeneron, AvenCell, SparingVision, Kyverna, ONK, and ReCode pay for technology access, research support, and milestone-linked development rights.

  • Patients with hereditary angioedemaprimary

    Future end users of lonvoguran ziclumeran, a one-time IV gene-editing therapy intended to reduce disease burden and attack frequency.

  • Patients with ATTR amyloidosisprimary

    Future end users of nexiguran ziclumeran, designed to address the root cause of transthyretin amyloid disease.

  • Specialty physicians and treatment centerssecondary

    Prescribers and infusion sites that would adopt and administer approved therapies in outpatient settings.

Intellia is headquartered in the United States and its business is centered on U.S.-based research, development, and...

  • •Headquartered and primarily operated in the United States
  • •Clinical development and corporate functions are U.S.-centered
  • •Collaborations create exposure to global partner and trial activity
  • •No country-level revenue disclosure was provided in the excerpts

Intellia is focused on advancing its in vivo CRISPR platform through late-stage clinical development and preparing for...

01
Phase 3 execution for lead programsshort-term

Clinical success is the main value driver and prerequisite for approval and commercialization.

02
Commercial launch preparationmedium-term

The company expects a potential first launch in 2027 and must build launch capabilities or partner for them.

03
Platform and delivery optimizationmedium-term

Better delivery and editing performance improve probability of success across current and future programs.

04
Capital efficiency through collaborationsshort-term

Collaboration revenue and reimbursements help fund operations before product sales begin.

Intellia faces the core risks of a clinical-stage gene-editing company: unproven technology, lengthy trials, regulatory...

critical

Clinical development failure

Lead programs are still in Phase 3, and adverse efficacy or safety data could eliminate commercialization prospects.

Scope
NTLA-2002 and NTLA-2001
Materiality
high
high

Unproven CRISPR platform

The company itself notes that CRISPR/Cas9 genome editing has only recently been clinically validated for human use.

Scope
Platform-wide
Materiality
high
high

Manufacturing and supply chain dependence

Clinical and future commercial supply rely on third parties for inputs, quality, and capacity.

Scope
Drug substance and product supply
Materiality
high
high

Commercialization execution risk

The company has no sales, marketing, or distribution infrastructure and may need to build one or partner.

Scope
Post-approval launch
Materiality
high
high

Financing and dilution risk

The business remains loss-making and may need additional capital before product revenue begins.

Scope
Runway and future funding
Materiality
high
Collaboration revenue recognition
Can create quarter-to-quarter volatility in reported revenue
Accrued research and development expenses
Affects operating expense timing and loss recognition
Stock-based compensation
Raises operating expenses without immediate cash outflow
Fair value measurements
Can affect net loss and other income
Lease accounting
Affects assets, liabilities, and non-cash disclosures

Lexeo Therapeutics, Inc.

LXEO · Biological Products, (No Diagnostic Substances)

Monopar Therapeutics

MNPR · Pharmaceutical Preparations

CRISPR Therapeutics AG

CRSP · Biological Products, (No Diagnostic Substances)

PROTHENA CORP PUBLIC LTD CO

PRTA · Pharmaceutical Preparations

Metagenomi Therapeutics, Inc.

MGX · Biological Products, (No Diagnostic Substances)

Larimar Therapeutics, Inc.

LRMR · Pharmaceutical Preparations

: 28/04/2026